TGFB1 and Hepatic fibrosis: Specifically, in a rat model of NASH, combining UDCA with losartan attenuated liver fibrosis, decreased intestinal permeability, and inhibited the expression of TGF-β1 and TLR4 with hepatic stellate cells activation (Namisaki et al., 2016).